Alkem Laboratories Limited
ALKEM · Pharma · NSE
₹5,554
Current Market Price
Fair Value (DCF)
₹5,781
Margin of Safety
+4.1%
Updated just now
YieldIQ Score
51/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
44%
ROE
17.4%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.66 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
19.0%
Return on capital employed
EV / EBITDA
20.9×
Enterprise multiple
Debt / EBITDA
0.7×
Leverage vs earnings
Interest Coverage
30.0×
EBIT covers interest
Current Ratio
2.76×
Short-term liquidity
Asset Turnover
0.69×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
14.3%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹5,553.5
Bear case
₹3,431.39
MoS -61.8%
Base case
₹5,780.77
MoS +3.9%
Bull case
₹7,932.99
MoS +30.0%
Ratio Trends
ALKEM · last 8 annual periods
ROE
17.4%
ROCE
21.5%
Operating Margin
—
Debt / Equity
0.11×
PE
159.4×
EV / EBITDA
24.4×
Historical Financials
ALKEM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹7220 Cr | ₹10.6K Cr | ₹2238 Cr | ₹2936 Cr | ₹12.8K Cr | +15.4% |
| EBITDA | — | ₹2189 Cr | ₹1709 Cr | ₹2418 Cr | ₹2971 Cr | +7.9% |
| EBIT | ₹1927 Cr | ₹1897 Cr | ₹351 Cr | ₹394 Cr | — | -32.7% |
| PAT | ₹1685 Cr | ₹1680 Cr | ₹255 Cr | ₹304 Cr | ₹2165 Cr | +6.5% |
| EPS (diluted) | ₹140.93 | ₹137.63 | ₹21.31 | ₹24.55 | — | -35.4% |
| CFO | ₹1324 Cr | ₹1111 Cr | ₹1437 Cr | ₹1948 Cr | ₹1913 Cr | +9.6% |
| CapEx | — | — | — | — | ₹-676 Cr | — |
| FCF | — | — | — | — | ₹1237 Cr | +0.0% |
| Total Assets | — | ₹14.1K Cr | ₹12.7K Cr | ₹15.6K Cr | ₹17.7K Cr | +5.9% |
| Total Debt | — | — | ₹1137 Cr | ₹1174 Cr | ₹1381 Cr | +5.0% |
| Shareholders' Equity | — | — | ₹9350 Cr | ₹10.3K Cr | ₹12.4K Cr | +7.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ALKEM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| GLENMARK GLENMARK | — | — | Pending | 11.8% | — |
| LAURUSLABS Laurus Labs Limited | -63.3% | 40 | Data Limited | 7.8% | — |
| AUROPHARMA Aurobindo Pharma Limited | +36.3% | 59 | Undervalued | 10.7% | — |
| ABBOTINDIA ABBOTINDIA | — | — | Pending | 33.4% | — |
| MANKIND Mankind Pharma Limited | -38.3% | 40 | Overvalued | 13.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
19 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹217.00/sh
Last payout
2026-02-20
₹43.00
Peak payout
₹43.00
Trailing yield
0.92%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Alkem Laboratories Limited (ALKEM.NS) trades at 5553.50 vs a model fair value of 5780.77, a gap of 4.1%. Piotroski F-score: 6/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ALKEM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ALKEM →
Compare
Head-to-head with peers
Compare ALKEM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ALKEMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.